
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (33): 4132-4139.DOI: 10.12114/j.issn.1007-9572.2024.0628
Special Issue: 心血管最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2024-11-04
Revised:2025-05-20
Published:2025-11-20
Online:2025-09-17
Contact:
SU Haiyan
通讯作者:
苏海燕
作者简介:作者贡献:
王碧优提出主要研究目标,负责研究的构思与设计,撰写文章初稿,对研究内容进行验证,保证研究结果的可重复性;高鹰、苏海燕负责文章的指导与修订;尤俊方、刘莉负责管理元数据、数据整理及维护;张卿负责文章的质量控制。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0628
| 组别 | 例数 | TG/HDL-C | TC/HDL-C | LDL-C/HDL-C | NLR | NMR | LMR | MHR | CRP(mg/L) |
|---|---|---|---|---|---|---|---|---|---|
| 低危组 | 4 718 | 0.88(0.56,1.36) | 3.55(3.00,4.19) | 2.23(1.74,2.74) | 1.67(1.32,2.10) | 7.93(6.52,9.59) | 4.74(3.88,5.81) | 0.27(0.20,0.36) | 0.69(0.34,1.48) |
| 中危组 | 1 575 | 1.26(0.86,1.91) | 4.02(3.44,4.67) | 2.56(2.06,3.07) | 1.67(1.33,2.16) | 7.48(6.25,8.96) | 4.48(3.57,5.56) | 0.33(0.25,0.42) | 1.00(0.54,2.02) |
| 高危组 | 1 225 | 1.33(0.95,1.98) | 4.21(3.53,4.78) | 2.70(2.17,3.16) | 1.81(1.41,2.37) | 7.58(6.32,9.03) | 4.18(3.37,5.22) | 0.37(0.29,0.46) | 1.22(0.61,2.47) |
| H值 | 684.12 | 550.39 | 421.29 | 48.82 | 57.81 | 170.65 | 613.21 | 333.74 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of baseline characteristic in different 10-year ASCVD risk groups
| 组别 | 例数 | TG/HDL-C | TC/HDL-C | LDL-C/HDL-C | NLR | NMR | LMR | MHR | CRP(mg/L) |
|---|---|---|---|---|---|---|---|---|---|
| 低危组 | 4 718 | 0.88(0.56,1.36) | 3.55(3.00,4.19) | 2.23(1.74,2.74) | 1.67(1.32,2.10) | 7.93(6.52,9.59) | 4.74(3.88,5.81) | 0.27(0.20,0.36) | 0.69(0.34,1.48) |
| 中危组 | 1 575 | 1.26(0.86,1.91) | 4.02(3.44,4.67) | 2.56(2.06,3.07) | 1.67(1.33,2.16) | 7.48(6.25,8.96) | 4.48(3.57,5.56) | 0.33(0.25,0.42) | 1.00(0.54,2.02) |
| 高危组 | 1 225 | 1.33(0.95,1.98) | 4.21(3.53,4.78) | 2.70(2.17,3.16) | 1.81(1.41,2.37) | 7.58(6.32,9.03) | 4.18(3.37,5.22) | 0.37(0.29,0.46) | 1.22(0.61,2.47) |
| H值 | 684.12 | 550.39 | 421.29 | 48.82 | 57.81 | 170.65 | 613.21 | 333.74 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|
| 1 | 0.569 | 0.478 | 0.668 | 217.551 | <0.001 |
| 2 | 0.100 | 0.010 | 0.988 | 11.789 | <0.001 |
| 3 | 0.049 | 0.002 | 0.998 | 6.041 | <0.001 |
Table 2 Canonical correlation analysis between lipid ratios and inflammatory markers
| 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|
| 1 | 0.569 | 0.478 | 0.668 | 217.551 | <0.001 |
| 2 | 0.100 | 0.010 | 0.988 | 11.789 | <0.001 |
| 3 | 0.049 | 0.002 | 0.998 | 6.041 | <0.001 |
| 变量 | U1 | U2 |
|---|---|---|
| X1(TG/HDL-C) | 1.172 | 1.998 |
| X2(TC/HDL-C) | -1.274 | -3.984 |
| X3(LDL-C/HDL-C) | 1.493 | 2.366 |
Table 3 The standardized correlation coefficient between lipid ratios and comprehensive variable of lipid ratios
| 变量 | U1 | U2 |
|---|---|---|
| X1(TG/HDL-C) | 1.172 | 1.998 |
| X2(TC/HDL-C) | -1.274 | -3.984 |
| X3(LDL-C/HDL-C) | 1.493 | 2.366 |
| 变量 | V1 | V2 |
|---|---|---|
| Y1(NLR) | -0.355 | 0.495 |
| Y2(NMR) | 0.435 | 0.335 |
| Y3(LMR) | 0.081 | -0.395 |
| Y4(MHR) | 1.117 | 0.141 |
| Y5(CRP) | 0.009 | -0.565 |
Table 4 The standardized correlation coefficient between inflammatory markers and comprehensive variable of inflammatory markers
| 变量 | V1 | V2 |
|---|---|---|
| Y1(NLR) | -0.355 | 0.495 |
| Y2(NMR) | 0.435 | 0.335 |
| Y3(LMR) | 0.081 | -0.395 |
| Y4(MHR) | 1.117 | 0.141 |
| Y5(CRP) | 0.009 | -0.565 |
| 分组 | 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|---|
| 低危组 | 1 | 0.573 | 0.490 | 0.661 | 140.403 | <0.001 |
| 2 | 0.110 | 0.012 | 0.984 | 9.263 | <0.001 | |
| 3 | 0.060 | 0.004 | 0.996 | 5.665 | 0.001 | |
| 中危组 | 1 | 0.552 | 0.439 | 0.680 | 43.178 | <0.001 |
| 2 | 0.142 | 0.020 | 0.979 | 4.166 | <0.001 | |
| 3 | 0.029 | 0.001 | 0.999 | 0.446 | 0.720 | |
| 高危组 | 1 | 0.496 | 0.326 | 0.739 | 25.898 | <0.001 |
| 2 | 0.135 | 0.019 | 0.980 | 3.059 | 0.002 | |
| 3 | 0.038 | 0.001 | 0.999 | 0.597 | 0.617 |
Table 5 Canonical correlation analysis between lipid ratios and inflammatory markers in different 10-year ASCVD risk groups
| 分组 | 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|---|
| 低危组 | 1 | 0.573 | 0.490 | 0.661 | 140.403 | <0.001 |
| 2 | 0.110 | 0.012 | 0.984 | 9.263 | <0.001 | |
| 3 | 0.060 | 0.004 | 0.996 | 5.665 | 0.001 | |
| 中危组 | 1 | 0.552 | 0.439 | 0.680 | 43.178 | <0.001 |
| 2 | 0.142 | 0.020 | 0.979 | 4.166 | <0.001 | |
| 3 | 0.029 | 0.001 | 0.999 | 0.446 | 0.720 | |
| 高危组 | 1 | 0.496 | 0.326 | 0.739 | 25.898 | <0.001 |
| 2 | 0.135 | 0.019 | 0.980 | 3.059 | 0.002 | |
| 3 | 0.038 | 0.001 | 0.999 | 0.597 | 0.617 |
| 分组 | 变量 | U1 | U2 |
|---|---|---|---|
| 低危组 | X1(TG/HDL-C) | 1.111 | -1.913 |
| X2(TC/HDL-C) | -1.446 | 5.599 | |
| X3(LDL-C/HDL-C) | 1.633 | -4.029 | |
| 中危组 | X1(TG/HDL-C) | 1.582 | -2.193 |
| X2(TC/HDL-C) | -1.576 | 3.744 | |
| X3(LDL-C/HDL-C) | 1.592 | -2.029 | |
| 高危组 | X1(TG/HDL-C) | 1.016 | -1.105 |
| X2(TC/HDL-C) | -0.565 | 1.122 | |
| X3(LDL-C/HDL-C) | 0.925 | 0.011 |
Table 6 The standardized correlation coefficient between lipid ratios and comprehensive variable of lipid ratios in different 10-year ASCVD risk groups
| 分组 | 变量 | U1 | U2 |
|---|---|---|---|
| 低危组 | X1(TG/HDL-C) | 1.111 | -1.913 |
| X2(TC/HDL-C) | -1.446 | 5.599 | |
| X3(LDL-C/HDL-C) | 1.633 | -4.029 | |
| 中危组 | X1(TG/HDL-C) | 1.582 | -2.193 |
| X2(TC/HDL-C) | -1.576 | 3.744 | |
| X3(LDL-C/HDL-C) | 1.592 | -2.029 | |
| 高危组 | X1(TG/HDL-C) | 1.016 | -1.105 |
| X2(TC/HDL-C) | -0.565 | 1.122 | |
| X3(LDL-C/HDL-C) | 0.925 | 0.011 |
| 分组 | 变量 | V1 | V2 |
|---|---|---|---|
| 低危组 | Y1(NLR) | -0.264 | -0.388 |
| Y2(NMR) | 0.370 | -0.377 | |
| Y3(LMR) | 0.159 | 0.568 | |
| Y4(MHR) | 1.099 | -0.145 | |
| Y5(CRP) | 0.028 | 0.420 | |
| 中危组 | Y1(NLR) | -0.496 | 0.237 |
| Y2(NMR) | 0.586 | -0.629 | |
| Y3(LMR) | 0.035 | 1.206 | |
| Y4(MHR) | 1.116 | -0.031 | |
| Y5(CRP) | -0.039 | 0.119 | |
| 高危组 | Y1(NLR) | -0.602 | -0.994 |
| Y2(NMR) | 0.644 | 0.224 | |
| Y3(LMR) | -0.008 | -0.222 | |
| Y4(MHR) | 1.110 | -0.188 | |
| Y5(CRP) | -0.017 | 0.782 |
Table 7 The standardized correlation coefficient between inflammatory markers and comprehensive variable of inflammatory markers in different 10-year ASCVD risk groups
| 分组 | 变量 | V1 | V2 |
|---|---|---|---|
| 低危组 | Y1(NLR) | -0.264 | -0.388 |
| Y2(NMR) | 0.370 | -0.377 | |
| Y3(LMR) | 0.159 | 0.568 | |
| Y4(MHR) | 1.099 | -0.145 | |
| Y5(CRP) | 0.028 | 0.420 | |
| 中危组 | Y1(NLR) | -0.496 | 0.237 |
| Y2(NMR) | 0.586 | -0.629 | |
| Y3(LMR) | 0.035 | 1.206 | |
| Y4(MHR) | 1.116 | -0.031 | |
| Y5(CRP) | -0.039 | 0.119 | |
| 高危组 | Y1(NLR) | -0.602 | -0.994 |
| Y2(NMR) | 0.644 | 0.224 | |
| Y3(LMR) | -0.008 | -0.222 | |
| Y4(MHR) | 1.110 | -0.188 | |
| Y5(CRP) | -0.017 | 0.782 |
| [1] |
马丽媛,王增武,樊静,等. 《中国心血管健康与疾病报告2021》要点解读[J]. 中国全科医学,2022,25(27):3331-3346.
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志,2023,38(3):237-271. DOI:10.3969/j.issn.1000-3614.2023.03.001.
|
| [6] |
郭才华,王启章,胡乔,等. 急性缺血性脑卒中患者脂肪因子Apelin、Vaspin、Leptin对出血转化的预测价值[J]. 心血管康复医学杂志,2021,30(3):269-273. DOI:10.3969/j.issn.1008-0074.2021.03.05.
|
| [7] |
|
| [8] |
|
| [9] | |
| [10] |
|
| [11] |
李梦兰,梁宾,曹树正,等. 系统性炎症指数在冠心病中的临床意义及诊断价值研究[J]. 国际检验医学杂志,2021,42(19):2329-2332.
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中国循环杂志,2019,34(1):4-28. DOI:10.3969/j.issn.1000-3614.2019.01.002.
|
| [16] | |
| [17] |
中国心血管病风险评估和管理指南编写联合委员会,顾东风. 中国心血管病风险评估和管理指南[J]. 中国循环杂志,2019,34(1):4-28. DOI:10.3760/cma.j.issn.0253-9624.2019.01.004.
|
| [18] |
陈欣,王丹,刘佳莉,等. 不同风险预测模型评估高血压人群10年心血管疾病风险的比较[J]. 中华高血压杂志,2023,31(10):929-936. DOI:10.16439/j.issn.1673-7245.2023.10.008.
|
| [19] |
陈瑞芳,黄俏,杨永红,等. 基于China-PAR模型正常高值血压与心血管病风险相关性研究[J]. 中国老年保健医学,2023,21(2):98-102.
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
董荣静,石柔,董雪娥,等. 中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值与2型糖尿病患者颈动脉粥样硬化的相关性[J]. 中华临床医师杂志(电子版),2017,11(2):179-182. DOI:10.3877/cma.j.issn.1674-0785.2017.02.001.
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
张京. 外周血炎症指标与颈动脉粥样硬化的相关性研究[D]. 武汉:江汉大学,2023. DOI:10.27800/d.cnki.gjhdx.2023.000299.
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [1] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| [2] | QIU Yanli, GAO Yongyin, BIAN Xueyan, WANG Xue, LI Yue. The Predictive Value of Estimated Pulse Wave Velocity for All-cause and Cardiovascular-related Mortality in Cancer Patients [J]. Chinese General Practice, 2026, 29(14): 1890-1897. |
| [3] | HU Jiaqi, LI Duan, FANG Hao, FAN Xingying, DU Wei, ZHOU Hanni. Study on Predictive Model of Non-genetic Risk Factors for Hyperuricemia in a Physical Examination Cohort [J]. Chinese General Practice, 2026, 29(10): 1324-1333. |
| [4] | YANG Xu, FAN Jieting, SONG Hongyan, FENG Panpan, HAO Jingyu, YAO Mi. Risk Assessment and Communication Strategies for Cardiovascular Diseases in Primary Care [J]. Chinese General Practice, 2026, 29(10): 1294-1299. |
| [5] | LI Qiuchun, SU Ping, PANG Jinhong, CHEN Qiaoqiao, ZHAO Yingying, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association of Triglyceride Glucose Index with Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 Population: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(09): 1129-1136. |
| [6] | SUN Qinyu, DENG Yifan, YANG Tianxiao, FANG Zhen, JI Jun, HE Shenghu, ZHANG Jing. Clinical Study of HbA1c/ApoA-1, TyG-BMI and Their Combination to Predict the Severity of Coronary Artery Calcification [J]. Chinese General Practice, 2026, 29(09): 1137-1145. |
| [7] | PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952. |
| [8] | LEI Yingying, ZHENG Siying, WANG Wenxin, JIANG Hong. Prevalence Trend and Prediction of Hypertensive Heart Disease in the World and China from 1990 to 2021 [J]. Chinese General Practice, 2026, 29(05): 641-648. |
| [9] | XIA Ying, WU Xinri, ZHANG Caiqin, HONG Xin. Distribution and Influencing Factors of Cardiovascular Health among Community Residents Based on the "Life's Essential 8" Score [J]. Chinese General Practice, 2026, 29(05): 597-605. |
| [10] | LU Yanqiu, WU Yuntao, LIU Shaopeng, LIN Haiying, DENG Huiyou, WU Ying, HUANG Zhe, YANG Peng, WU Shouling, LI Yun. Effect of Blood Pressure Trajectory on Cardiovascular Disease in Population with High-normal Blood Pressure: a Study Based on the Kailuan Cohort [J]. Chinese General Practice, 2026, 29(03): 299-310. |
| [11] | FAN Zhuanzhuan, LI Wenting, MA Guoliang. Relationship between the Chinese Visceral Adipose Index and Cardiovascular Disease in Postmenopausal Women: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(02): 180-187. |
| [12] | DIJI Zhuoma, ZOU Yanqiu, ZHENG Dixin, HU Mengjie, LIU Xiaoxue, JIANG Xia, FAN Mengyu, LI Jiayuan. Association of Social Isolation, Loneliness, with Incidence Risk of Cardiovascular Diseases: a Prospective Chinese Study [J]. Chinese General Practice, 2026, 29(01): 122-128. |
| [13] | ZHANG Shu, CHENG Yu, WU Shouling, CHEN Shuohua, WU Yuntao. The Impact of Cumulative Plasma Atherogenic Index Exposure on Incident Cardiovascular Disease in Non-Diabetic Individuals: a Cohort Study [J]. Chinese General Practice, 2025, 28(36): 4558-4565. |
| [14] | LIU Ruiyue, YANG Xuemei, ZHAO Naihui, WEN Xinran, CAI Xi, LIANG Yajing, MA Jiajia, WU Shouling, CUI Liufu. The Impact of the Ratio of High-sensitivity C-reactive Protein to Albumin on Incident Cardiovascular Disease in Different Age Groups: a Cohort Study [J]. Chinese General Practice, 2025, 28(36): 4566-4577. |
| [15] | ZHANG Ying, LIAO Xiaoyang, YANG Hanfei, YU Yongjun, LIU Lidi, JIA Yu, SHEN Can, LI Xiao, HUANG Chuanying, YANG Rong. Interpretation of the 2024 International Society of Hypertension Position Paper on Innovations in Blood Pressure Measurement and Reporting Technology and Its Implications for China [J]. Chinese General Practice, 2025, 28(36): 4541-4549. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||